乳腺癌组织中多药耐药相关蛋白的表达及其临床意义  

Expressions and significance of multidrug resistance related proteins in breast cancer

作　　者：王绍奎[1] 张维浩[1] 孙兰萍[2] 孙翔宇[2] 赵炎[2] 左文述[3] 

机构地区：[1]高青县人民医院肿瘤科,山东高青256300 [2]山东省肿瘤医院病理科,山东济南250117 [3]山东省肿瘤医院乳腺病防治中心,山东济南250117

出　　处：《中华肿瘤防治杂志》2007年第9期692-694,共3页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:探讨P-gp、LRP、GST-π和Topo-Ⅱ在乳腺癌组织中的表达及术前化疗对乳腺癌多药耐药的影响和临床意义。方法:采用免疫组织化学SP法,对18例术前曾用化疗和70例术前未用化疗的88例乳腺癌组织检测P-gp、LRP、GST-π和Topo-Ⅱ的表达。结果:88例乳腺癌中P-gp、LRP、GST-π和Topo-Ⅱ的阳性率分别为42.0%、53.4%、48.9%和40.9%。术前应用化疗的的患者癌组织P-gp、LRP和GST-π三者阳性表达率均较未用化疗的患者高,P-gp和LRP差异有统计学意义(P<0.05),而GST-π差异无统计学意义,P>0.05。Topo-Ⅱ有化疗史的患者比无化疗史的患者低,但差异无统计学意义,P>0.05。结论:P-gp、LRP、GST-π和Topo-Ⅱ的耐药机制各不相同,同时检测P-gp、LRP、GST-π和Topo-Ⅱ等多种导致多药耐药的因素,对乳腺癌化疗有重要的指导意义。OBJECTIVE： To investigate the relationship between the expressions of P gp, LRP. （GST-π and Topo-Ⅱ and neoadjuvant chemotherapy in breast cancer. METHODS： By using immunohistochemical SP method, the expressions of P-gp, LRP, GST xand Topo- Ⅱ were detected in 18 patients with breast cancer treated by chemotherapy before surgery and 70 cases of non-chemotherapy. RESULTS： The positive rates of P-gp, LRP, （GST-π and Topo-Ⅱ were 42. 0%, 53.4%, 48. 9%, 40. 9%, respec tively in 88 cases of breast cancer. The P-gp and LRP posi tive expressions in cases of non-chcmothcrapy were 35.7 and 47. 1 %, respectively, but it increased significantly in the neoadjuvant chemotherapy group, P〈0.05. CONCLUSION： Combining examination of P gp, LRP, GST-π and Topo- Ⅱmay have a guideline significance for chemotherapy of breast cancer.

关 键 词：乳腺肿瘤/药物疗法 抗药性 多药 免疫组织化学 

分 类 号：R737.9[医药卫生—肿瘤]